General Announcement::GPL Announces Initiation of a Phase 2b Trial of GBR 830 for the Treatment of Atopic Dermatitis

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
17-Apr-2018 12:31:05
Status
New
Announcement Sub Title
GPL Announces Initiation of a Phase 2b Trial of GBR 830 for the Treatment of Atopic Dermatitis
Announcement Reference
SG180417OTHRN69K
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Ltd.
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
17/04/2018 09:19:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals Announces Initiation of a Phase 2b Trial of GBR 830, a First in Class, Investigational, Anti OX40 Monoclonal Antibody for the Treatment of Moderate to Severe Atopic Dermatitis

Attachments

PR_17042018.pdf
Total size =304K